



Celgene Corporation
Investor Relations Department
86 Morris Avenue
Summit, NJ 07901
United States

[Visit IR website](#)
[Sign-up for e-mail alerts](#)

NASDAQ: CELG

Last Trade:	79.44
Trade Time:	4:00 PM ET Jun 19, 2018
Change:	1.71 (2.200%)
Day Range	77.14 - 79.58
52-Week Range	74.13 - 147.17
Volume	8,047,600

Stock information is provided by eSignal,
stock charts provided by EDGAR Online.
Stock data is delayed approximately 20
minutes.

Company Profile

Celgene Corporation is a global biopharmaceutical company engaged in the discovery, development and commercialization of innovative therapies for the treatment of cancer and immune-inflammatory related diseases. Our portfolio of commercial products include REVLIMID[®], VIDAZA[®], THALOMID[®], POMALYST[®]/IMNOVID[®], ABRAXANE[®], OTEZLA[®], ISTODAX[®] and IDHIFA[®]. The drug candidates in our pipeline are at various stages of preclinical and clinical development. These cand... [\(more\)](#)

Stock Performance



Press Releases [\[View all \]](#)

Jun 19, 2018

[Celgene Corporation Announces Appointment of Jonathan Biller as Executive Vice President and General Counsel Following the Departure of Gerald F. Masoudi](#)

Jun 3, 2018

[Celgene Announces Updated Safety and Efficacy Data from the TRANSCEND Trial of liso-cel \(JCAR017\) in Patients with Relapsed or Refractory B-cell non-Hodgkin Lymphoma at ASCO](#)

Jun 3, 2018

[Results of Phase III RELEVANCE Study Comparing REVLIMID plus Rituximab \(R²\) Versus Rituximab Plus Chemotherapy in Patients with Previously Untreated Follicular Lymphoma to be Presented at ASCO 2018](#)

Jun 1, 2018

[Updated Results of Ongoing Multicenter Phase I Study of bb2121 anti-BCMA CAR T Cell Therapy Continue to Demonstrate Deep and Durable Responses in Patients with Late-Stage Relapsed/Refractory Multiple Myeloma at ASCO Annual Meeting](#)

Jun 1, 2018

[Results of Phase III OPTIMISMM Study Presented at ASCO 2018 Showed the PVd Triplet Improved PFS in Early Lines of](#)

Financials [\[View all \]](#)

Feb 7, 2018

[Annual Report \(10-K\)](#)

Apr 30, 2018

[Proxy Statement \(DEF 14A\)](#)

May 4, 2018

[Quarterly Report \(10-Q\)](#)

Oct 26, 2017

[Quarterly Report \(10-Q\)](#)

Jul 27, 2017

[Quarterly Report \(10-Q\)](#)

